Adial Pharmaceuticals, Inc. has announced a prospectus for the potential offering of up to $100,000,000 in securities, which may include common stock, preferred stock, debt securities, warrants, or units. The securities may be offered from time to time in various transactions at fixed prices, prevailing market prices, or negotiated prices. The specific terms of any offering, such as the names of underwriters, dealers, or agents, purchase price, and net proceeds, will be detailed in future prospectus supplements. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'ADIL.' As of January 19, 2024, the last reported sale price of Adial's common stock was $1.275 per share. The company has not sold any shares of common stock under General Instruction I.B.6 to Form S-3 in the twelve months preceding the date of the prospectus. Investing in the securities involves risks, which are detailed under the heading 'Risk Factors' in the prospectus.

Adial Pharmaceuticals, Inc. has announced a prospectus for the potential offering of up to $100,000,000 in securities, which may include common stock, preferred stock, debt securities, warrants, or units. The securities may be offered from time to time in various transactions at fixed prices, prevailing market prices, or negotiated prices. The specific terms of any offering, such as the names of underwriters, dealers, or agents, purchase price, and net proceeds, will be detailed in future prospectus supplements. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'ADIL.' As of January 19, 2024, the last reported sale price of Adial's common stock was $1.275 per share. The company has not sold any shares of common stock under General Instruction I.B.6 to Form S-3 in the twelve months preceding the date of the prospectus. Investing in the securities involves risks, which are detailed under the heading 'Risk Factors' in the prospectus.